Jim Cramer Gives His Opinion On AstraZeneca, Cummins And Dow Chemical

Jim Cramer spoke on the show about

. He was negative on the stock for a long time, but he changed his mind because of an upgrade by Morgan Stanley on December 1. The analyst wrote that the company is going to make $4.20 per share in 2016, because it should benefit from changes in research and development. The company is going to have three new clinical trials and it is expected to bring three new drugs to the market in 2016, which could be worth $9 billion. Cramer likes

and he is a buyer of the stock. He also commented on

. He said that the stock is struggling and he is not ready to call a bottom yet, although he thinks that there might not be much more downside. Cramer thinks so because the stock got downgraded by Bank Of America from Buy to Underperform on December 1, after it had a Buy rating when it was trading at $142. He also likes its 4.5 percent dividend yield and he believes that its dividend is sustainable. Cramer said that he likes

and he is looking to buy more.